Epigenetic modulation of human breast cancer by metallofullerenol nanoparticles: In vivo treatment and in vitro analysis

Nanoscale

Volumn 3, Issue 11, 2011, Pages 4713-4719

  Meng, Jie ^a   Xing, Jianmin ^c   Wang, Yingze ^a   Lu, Juan ^a   Zhao, Yuliang ^a,b   Gao, Xueyun ^b   Wang, Paul C ^d   Jia, Lee ^a   Liang, Xingjie ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^b INSTITUTE OF HIGH ENERGY PHYSICS   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d HOWARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMOR ACTIVITIES; ANTI-TUMORS; CDNA MICROARRAYS; CELL LINES; CELL VIABILITY; CELLULAR SIGNALING; ENDOHEDRALS; HIERARCHICAL CLUSTER ANALYSIS; HUMAN BREAST CANCER; HUMAN UMBILICAL VEINS; IN-VITRO; IN-VITRO ANALYSIS; IN-VIVO; LOW TOXICITY; MECHANISM OF ACTION; MOLECULAR MECHANISM; PHYSICOCHEMICAL CHARACTERISTICS; REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION; SEMI-QUANTITATIVE; WESTERN-BLOT ANALYSIS;

CELL CULTURE; CELLS; CHEMICAL ANALYSIS; CLUSTER ANALYSIS; DISEASES; ENZYME INHIBITION; GADOLINIUM; HIERARCHICAL SYSTEMS; POLYMERASE CHAIN REACTION;

NANOPARTICLES;

FULLERENE DERIVATIVE; FULLERENOL; GADOLINIUM; NANOCAPSULE; NANOMATERIAL;

ARTICLE; BREAST TUMOR; CELL SURVIVAL; CHEMISTRY; CRYSTALLIZATION; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; HUMAN; METHODOLOGY; NANOMEDICINE; PARTICLE SIZE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CRYSTALLIZATION; EPIGENESIS, GENETIC; FULLERENES; GADOLINIUM; HUMANS; NANOCAPSULES; NANOMEDICINE; NANOSTRUCTURES; PARTICLE SIZE; TREATMENT OUTCOME;

EID: 84856422869     PISSN: 20403364     EISSN: 20403372     Source Type: Journal    
DOI: 10.1039/c1nr10898k     Document Type: Article

References (29)

1. X. Ma D. Wang Y. Wu R. J. Ho L. Jia P. Guo L. Hu G. Xing Y. Zeng X. J. Liang AIDS Treatment with Novel Anti-HIV Compounds Improved by Nanotechnology AAPS J. 2010 12 272 278
2. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discovery 2003 2 347 360 (Pubitemid 37361705)
3. J. J. Yin F. Lao P. P. Fu W. G. Wamer Y. Zhao P. C. Wang Y. Qiu B. Sun G. Xing J. Dong X. J. Liang C. Chen The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials Biomaterials 2009 30 611 621
4. N. Nishiyama S. Okazaki H. Cabral M. Miyamoto Y. Kato Y. Sugiyama K. Nishio Y. Matsumura K. Kataoka Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice Cancer Res. 2003 63 8977 8983 (Pubitemid 38064079)
5. 22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity Biomaterials 2009 30 3934 3945
6. n nanoparticles: antineoplastic activity of high efficiency and low toxicity Nano Lett. 2005 5 2050 2057 (Pubitemid 41546336)
7. Y. Wang L. V. Juan X. Ma D. Wang H. Ma Y. Chang G. Nie L. Jia X. Duan X. J. Liang Specific hemosiderin deposition in spleen induced by a low dose of cisplatin: altered iron metabolism and its implication as an acute hemosiderin formation model Curr. Drug Metab. 2010 11 507 515
8. X. J. Liang H. Meng Y. Wang H. He J. Meng J. Lu P. C. Wang Y. Zhao X. Gao B. Sun C. Chen G. Xing D. Shen M. M. Gottesman Y. Wu J. J. Yin L. Jia Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis Proc. Natl. Acad. Sci. U. S. A. 2010 107 7449 7454
9. H. Meng G. Xing B. Sun F. Zhao H. Lei W. Li Y. Song Z. Chen H. Yuan X. Wang J. Long C. Chen X. Liang N. Zhang Z. Chai Y. Zhao Potent angiogenesis inhibition by the particulate form of fullerene derivatives ACS Nano 2010 4 2773 2783
10. W. Krätschmer L. D. Lamb K. Fostiropoulos D. R. Huffman Solid C60:a new form of carbon Nature 1990 347 354 357
11. B. Sun L. Feng Z. Shi Z. Gu Improved extraction of metallofullerences with DMF at high temperature Carbon 2002 40 1591 1595 (Pubitemid 34623852)
12. Y. Zhao Z. Chen H. Yuan X. Gao L. Qu Z. Chai G. Xing S. Yoshimoto E. Tsutsumi K. Itaya Highly selective and simple synthesis of C(2)(m)-X-C(2)(n) fullerene dimers J. Am. Chem. Soc. 2004 126 11134 11135 (Pubitemid 39223170)
13. G. Xing J. Zhang Y. Zhao J. Tang B. Zhang X. Gao H. Yuan L. Qu W. Cao Z. Chai K. Ibrahim R. Su Influences of structural properties on stability of fullerenols J. Phys. Chem. B 2004 108 11473 11479
14. J. Meng D. L. Wang P. C. Wang L. Jia C. Chen X. J. Liang Biomedical activities of endohedral metallofullerene optimized for pharmaceutics J. Nanosci. Nanotechnol. 2010 10 8610 8616
15. P. Mroz A. Pawlak M. Satti H. Lee T. Wharton H. Gali T. Sarna M. R. Hamblin Functionalized fullerenes mediate photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism Free Radical Biol. Med. 2007 43 711 719 (Pubitemid 47102125)
16. H. Hashizume P. Baluk S. Morikawa et al. Openings between defective endothelial cells explain tumor vessel leakiness Am. J. Pathol. 2000 156 1363 1380 (Pubitemid 30660013)
17. A. L. Edinger C. B. Thompson Death by design: apoptosis, necrosis and autophagy Curr. Opin. Cell Biol. 2004 16 663 669 (Pubitemid 39463117)
18. C. Palermo J. A. Joyce Cysteine cathepsin proteases as pharmacological targets in cancer Trends Pharmacol. Sci. 2008 29 22 28
19. S. B. Brown E. A. Brown I. Walker The present and future role of photodynamic therapy in cancer treatment Lancet Oncol. 2004 5 497 508 (Pubitemid 39069400)
20. S. Petanceska P. Canoll L. A. Devi Expression of rat cathepsin S in phagocytic cells J. Biol. Chem. 1996 271 4403 4409 (Pubitemid 26070548)
21. T. Flannery D. Gibson M. Mirakhur S. McQuaid C. Greenan A. Trimble B. Walker D. McCormick P. G. Johnston The clinical significance of cathepsin S expression in human astrocytomas Am. J. Pathol. 2003 163 175 182 (Pubitemid 36759602)
22. E. Ryschich P. Lizdenis C. Ittrich A. Benner S. Stahl A. Hamann J. Schmidt P. Knolle B. Arnold G. J. Hammerling R. Ganss Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma Cancer Res. 2006 66 198 211 (Pubitemid 43166026)
23. B. Wang J. Sun S. Kitamoto M. Yang A. Grubb H. A. Chapman R. Kalluri G. P. Shi Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors J. Biol. Chem. 2006 281 6020 6029 (Pubitemid 43847703)
24. Y. Yang S. K. Lim L. Y. Choong H. Lee Y. Chen P. K. Chong H. Ashktorab T. T. Wang M. Salto-Tellez K. G. Yeoh Y. P. Lim Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins J. Proteome Res. 2010 9 4767 478
25. Y. Yang Q. J. Lv Q. Y. Du B. H. Yang R. X. Lin S. Q. Wang Combined effects of Cantide and chemotherapeutic drugs on inhibition of tumor cells' growth in vitro and in vivo World J Gastroenterol 2005 11 2491 2496 (Pubitemid 40667988)
26. M. Daugaard M. Jäättelä M. Rohde Hsp70-2 is required for tumor cell growth and survival Cell Cycle 2005 4 877 880 (Pubitemid 41359749)
27. M. Rohde M. Daugaard M. H. Jensen K. Helin J. Nylandsted M. Jäättelä Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms Genes Dev. 2005 19 570 582 (Pubitemid 40314989)
28. D. R. Green J. C. Reed Mitochondria and apoptosis Science 1998 281 1309 1312 (Pubitemid 28406816)
29. S. Kitada C. L. Kress M. Krajewska L. Jia M. Pellecchia J. C. Reed Bcl-2 antagonist ApoGossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with less toxicity compared to Gossypol (NSC19048) Blood 2008 111 3211 3219